Health

#SFHS2614905VCorrection to Patient Contribution Rate for Rivaroxaban Viatris Santé

🇫🇷France··Other·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This notice corrects the patient contribution rate for one pharmaceutical product, Rivaroxaban Viatris Santé 10 mg tablets. The correct rate is 35%, not 85%. The change affects pharmacies, health insurers, billing teams, and patients using this medicine. It is a narrow technical correction to a previously published notice.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Corrects the patient contribution rate for Rivaroxaban Viatris Santé 10 mg tablets
  • Changes the listed rate from 85% to 35%
  • Applies only to the specified product presentation and CIP number

Obligations

What this law requires

medium

Apply a 35% patient contribution rate, instead of 85%, for RIVAROXABAN VIATRIS SANTE 10 mg film-coated tablets, CIP 34009 303 366 6 3, pack B/30x1.

pharmacieshealth insurerspharmaceutical billing teams
From the corrected notice as published; no specific compliance deadline stated
operational

Affected Parties

Patients using Rivaroxaban Viatris Santé 10 mgPharmacies and healthcare billing teams+1 more…

Tags

pharmaceuticals,patient contribution,rivaroxaban